Table 2.
Effect of different DPP-4 inhibitors, 5-hydroxy saxagliptin, or GLP-1 on the ex vivo function of hearts of aged diabetic high fat diet-fed mice (DM-HFD) at baseline and 40 min after ischemia perfusion (R40).
| LVDP (cmH2O) | dP/dtmax (cmH2O × ms−1) | dP/dtmin (cmH2O × ms−1) | Heart Rate (bpm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Baseline | R40 | Baseline | R40 | Baseline | R40 | Baseline | R40 | |
| Age-matched control + Vehicle | 17 | 101 ± 30 | 25 ± 19 | 3777 ± 1913 | 1274 ± 1011 | −2600 ± 960 | −1295 ± 1240 | 275 ± 101 | 337 ± 98 |
| DM-HFD + Vehicle | 15 | 90 ± 27 | 21 ± 14 | 3433 ± 1021 | 1266 ± 796 | −2541 ± 604 | −1152 ± 692 | 295 ± 83 | 293 ± 139 |
| DM-HFD + Linagliptin | 18 | 103 ± 22 | 38 ± 16 ab | 3951 ± 1856 | 1920 ± 1295 | −2763 ± 946 | −1639 ± 1521 | 288 ± 87 | 327 ± 86 |
| DM-HFD + Sitagliptin | 14 | 81 ± 39 | 14 ± 11 c | 3139 ± 1894 | 1065 ± 870 | −2156 ± 1143 | −913 ± 760 | 311 ± 91 | 320 ± 108 |
| DM-HFD + Alogliptin | 17 | 83 ± 28 | 20 ± 19 d | 3422 ± 2024 | 1212 ± 949 | −2483 ± 1361 | −1313 ± 1475 | 297 ± 114 | 362 ± 148 |
| DM-HFD + Saxagliptin | 15 | 81 ± 15 | 15 ± 11 c | 3219 ± 1620 | 1156 ± 1099 | −2251 ± 993 | −957 ± 842 | 278 ± 94 | 321 ± 135 |
| DM-HFD + 5-hydroxy saxagliptin | 15 | 69 ± 54 | 14 ± 11 ac | 2578 ± 2275 | 805 ± 871 | −1744 ± 1393 aef | −672 ± 732 | 237 ± 73 | 317 ± 106 |
| DM-HFD + GLP-1 | 18 | 96 ± 39 | 21 ± 17 e | 3929 ± 1486 | 1400 ± 937 | −2981 ± 839 gh | −1287 ± 758 | 311 ± 93 | 346 ± 91 |
Values are mean ± S.D. a p < 0.05 vs. control + vehicle, b p < 0.01 vs. DM-HFD + vehicle, c p < 0.0001 vs. DM-HFD + linagliptin, d p < 0.001 vs. DM-HFD + linagliptin, e p < 0.01 vs. DM-HFD + linagliptin, f p < 0.05 vs. DM-HFD + vehicle, g p < 0.05 vs. DM-HFD + sitagliptin, h p < 0.01 vs. DM-HFD + 5-hydroxy saxagliptin by 1-way ANOVA followed by Fisher least significant difference post hoc test. bpm = beats per minute.